Skip to main content

Table 2 Prescription patterns of csDMARDs (MTX, LFN y SSZ) and GCs before the firs TNF antagonist

From: Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

Treatment First TNF antagonist monotherapy First TNF antagonist plus one csDMARD First TNF antagonist plus two or more csDMARDs Total P*
  n % n % n % n %  
  234 21 766 67 136 12 1.136 100  
Previous use of DMARDs (MTX, LFN, SSZ) and/or PDN) (n , %) 229 98 712 93 130 96 1,071 94  
None (n, %) 5 2 54 7 6 4 65 6 0.0001
One (n, %)          < 0.001
 PDN 8 3 139 18 76 56 223 20
 MTX + PDN 47 20 122 16 9 7 178 16
 LFN + PDN 17 7 106 14 8 6 131 11
 LFN 1 0.4 41 5 2 1 44 4
 SSZ + PDN 3 1 29 4 12 9 44 4
 MTX 5 2 33 4 1 0.7 39 3
 SSZ 4 2 11 1 1 0.7 16 1
 Total (MTX, LFN, SSZ) 77 33 342 45 33 24 452 40
 Total PDN 75 32 396 52 105 77 576 51
Two (n, %)          < 0.001
 LFN + MTX + PDN 67 29 89 12 12 9 168 15
 LFN + MTX 16 7 26 3 2 1 44 4
 SSZ + MTX + PDN 15 6 31 4 3 2 49 4
 SSZ + LFN + PDN 4 2 38 5 2 1 44 4
 SSZ + MTX 8 3 14 2 1 0.7 23 2
 SSZ + LFN 1 0.4 6 0.7 0 0 7 0.6
 Total (MTX, LFN, SSZ) 111 48 204 27 20 15 335 30
 Total PDN 86 37 158 21 17 12 218 20
Three (n, %)          < 0.001
 MTX + SSZ + LFN 6 2 6 0.7 1 0.7 13 1
 MTX + SSZ + LFN + PDN 27 12 21 3 0 0 48 4
 Total (MTX, LFN, SSZ) 33 14 27 3 1 0.7 61 5
 Total PDN 27 12 21 3 0 3 48 4
Previous exposure to MTX (n, %) 191 83 343 45 29 21 563 50 0.03
 Reason for discontinuation         
 Inefficacy 92 48 212 62 16 55 320 57
 Non-serious adverse event 91 48 121 35 13 45 225 40
 Serious adverse event 8 4 10 3 0 0 18 3
Previous exposure to LFN (n, %) 139 60 338 44 27 20 505 44 < 0.0001
 Reason for discontinuation         
 Inefficacy 64 46 229 68 16 59 309 62
 Non-serious adverse event 69 50 104 31 11 41 184 36
 Serious adverse event 6 4 5 1 0 0 11 2
Previous exposure to SSZ (n, %) 68 29 157 20 20 15 245 21 0.0001
Reason for discontinuation (n, %)         
 Inefficacy 17 50 46 63 1 33 64 26
 Non-serious adverse event 18 47 26 36 2 66 46 19
 Serious adverse event 0 0 1 1 0 0 2 0.8
Previous exposure to PDN ( n,%) 188 80 575 75 122 90 885 78 < 0.0001
  1. csDMARD conventional synthetic disease-modifying antirheumatic drug, DMARD disease-modifying antirheumatic drug, MTX methotrexate, LFN leflunomide, SSZ sulfasalazine, PDN prednisone